Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral recombinant helicobacter pylori protein vaccine nanoparticles and preparation method thereof

A Helicobacter pylori protein vaccine technology, applied in the field of oral recombinant Helicobacter pylori protein vaccine nanoparticles and its preparation, can solve the problems of poor absorption and poor permeability

Active Publication Date: 2021-11-16
CHONGQING MEDICAL UNIVERSITY
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oral recombinant protein vaccine α1,3-fucosyltransferase nanoparticles overcome the poor permeability of α1,3-fucosyltransferase, poor intestinal absorption, and difficulty in being absorbed by antigen-presenting cells (macrophages, etc.) in lymphoid tissues. ) uptake and other shortcomings, the nanoparticles of the present invention can not only improve the in vivo intestinal absorption of α1,3-fucosyltransferase and model antigen, but also improve the uptake of α1,3-fucosyltransferase and Model antigen capacity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral recombinant helicobacter pylori protein vaccine nanoparticles and preparation method thereof
  • Oral recombinant helicobacter pylori protein vaccine nanoparticles and preparation method thereof
  • Oral recombinant helicobacter pylori protein vaccine nanoparticles and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] The content of α1,3-fucosyltransferase is 2.40 mg / mL, and the weight ratio of other components in the formula is: polylactic acid-glycolic acid copolymer (the monomer ratio of lactic acid and glycolic acid is 75:25, Hereinafter referred to as: L:G is 75:25) 0.40 parts, hydroxypropyl methylcellulose phthalate HP55 is 0.20 parts, 2-hydroxypropyltrimethylammonium chloride chitosan 0.02 parts, Pluronic F-68 is 0.60 parts, distilled water is 90 parts.

[0028] Preparation method: (1) Dissolve the polylactic acid-glycolic acid copolymer (the monomer ratio of lactic acid and glycolic acid is 75:25) and hydroxypropyl methylcellulose phthalate (model HP55) of the prescription amount Form solution A in dichloromethane, dissolve the prescribed amount of α1,3-fucosyltransferase in distilled water, add to solution A, mix, and obtain emulsion B after ultrasonication in an ice bath; (2) Dissolve a certain amount of Pluronic (Model F-68) in distilled water, dissolve the prescribed amo...

Embodiment 2

[0030] The content of α1,3-fucosyltransferase is 3.90 mg / mL, and the weight composition ratio of the other components in the formula is: 0.65 parts of polylactic acid-glycolic acid copolymer (L:G is 50:50), hydroxyl Propyl methylcellulose phthalate HP50 is 0.325 parts, 2-hydroxypropyltrimethylammonium chloride chitosan is 0.0325 parts, Pluronic F-68 is 0.975 parts, and distilled water is 146.25 parts.

[0031] Preparation method: (1) Dissolve the prescribed amount of polylactic acid-glycolic acid copolymer and hydroxypropyl methylcellulose phthalate HP50 in chloroform to form solution A, and the prescribed amount of α1,3-rock After the algal glycosyltransferase is dissolved in distilled water, add it to solution A, mix, and obtain emulsion B after ultrasonication in an ice bath; (2) dissolve the prescribed amount of Pluronic F-68 in distilled water, and add the prescribed amount of Dissolve 2-hydroxypropyltrimethylammonium chloride chitosan in distilled water, quickly put emul...

Embodiment 3

[0033] The content of α1,3 fucosyltransferase is 1.20 mg / mL, and the weight composition ratio of the other components in the formula is: 0.20 part of polylactic acid-glycolic acid copolymer (L:G is 75:25), hydroxypropyl 0.10 parts of methylcellulose phthalate HP55, 0.01 parts of 2-hydroxypropyltrimethylammonium chloride chitosan, 0.30 parts of Pluronic F-127, and 45 parts of distilled water.

[0034] Preparation method: (1) Dissolve the prescribed amount of polylactic acid-glycolic acid copolymer and hydroxypropyl methylcellulose phthalate HP55 in acetone to form solution A, and the prescribed amount of α1,3-fucose After the base transferase is dissolved in distilled water, add it to solution A, mix, and obtain emulsion B after ultrasonication in an ice bath; (2) dissolve the prescribed amount of Pluronic F-127 in distilled water, and add the prescribed amount of 2- Dissolve hydroxypropyltrimethylammonium chloride chitosan in distilled water, quickly put the emulsion B into an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of pharmaceutical preparations, and relates to a recombinant protein vaccine alpha 1,3-fucosyltransferase nanoparticle and a preparation method thereof. The recombinant protein vaccine alpha 1,3-fucosyltransferase nanoparticles prepared by the invention not only can improve the absorption of alpha 1,3-fucosyltransferase in body intestines, but also can improve the ability of macrophages to take in alpha 1,3-fucosyltransferase, and can be used for preventing and treating infection caused by helicobacter pylori.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to an oral recombinant Helicobacter pylori protein vaccine nanoparticle and a preparation method thereof. Background technique [0002] Helicobacter pylori infection can cause gastroduodenal diseases. Vaccines are widely used around the world as a preventive and therapeutic method, but vaccines often need to be administered by injection, and patients’ compliance is poor. Oral administration is the most compliant of patients. route of administration. Recombinant protein vaccine α1,3-fucosyltransferase can help Helicobacter pylori evade host immune surveillance and play an important role in the colonization and long-term infection of Helicobacter pylori, but it has poor permeability and is difficult to be absorbed by the intestinal tract. The shortcomings such as the uptake of antigen-presenting cells (macrophages, etc.) in lymphoid tissues limit the wide application of this ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/02A61K38/45A61K39/39A61K9/00A61K9/51A61K47/34A61K47/38A61K47/36A61P31/04B82Y5/00B82Y40/00
CPCA61K39/0208A61K38/45A61K39/39A61K9/0053A61K9/5153A61K9/5161A61K9/5192A61P31/04B82Y5/00B82Y40/00C12Y204/01065A61K2039/55583A61K2039/542A61K2300/00Y02A50/30
Inventor 张景勍徐靖鑫王婷婷杨婕何丹
Owner CHONGQING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com